Back to search

Article

Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers

2025-03-19

Abstract excerpt

<title>Abstract</title> <p>Rapamycin, known for its anti-aging properties, shows promise as a preventive strategy for Alzheimer’s disease (AD) in APOE4 carriers—the highest-risk group for late-onset AD. Here we show that a 4-week open-label trial of low-dose Rapamycin (Sirolimus; 1 mg/day) significantly improved cerebral blood flow (CBF) relative to baseline in cognitively normal APOE4 carriers (E4(+)) aged 45–65...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fdb7247f-9a30-5c36-8e10-fe939fef68e5
DOI
10.21203/rs.3.rs-6214340/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriersDOI 10.21203/rs.3.rs-6214340/v1
Select a neighboring publication to make it the new centre.